MAM
Bugspeaks by Leucine Rich Bio launches “Happy Gut Mission” campaign
Mumbai: Leucine Rich Bio- South Asia’s first microbiome company, announced the launch of its “Happy Gut Mission” campaign, aimed at promoting better digestive wellness. Leveraging its cutting-edge microbiome analysis technology, Bugspeaks, the campaign seeks to inform the public about the significance of gut health and provide personalised insights that have the potential to revolutionize everyday dietary choices and lifestyle decisions.
The campaign highlights the crucial role that everyday lifestyle habits and dietary improvements play in fostering a healthier gut for youngsters as well as the older generation. As gut health becomes increasingly important for overall well-being, Leucine Rich Bio’s Happy Gut Mission will urge people to take control of their digestive health through a focus on nutrition, lifestyle changes, effective screening such as through cutting-edge microbiome testing with the support of BugSpeaks etc., BugSpeaks is a South Asia’s first microbiome test and recently showed the impressive result in a clinical trial with Type 2 diabetes, the findings of which were published in a prestigious international peer-reviewed journal. Leucine Rich Bio recently launched BugSpeaks2.0 which represents the next leap forward in microbiome testing and personalized health solutions.
“Understanding the importance of gut health is the first step towards improving it. With the Happy Gut Mission campaign, we are committed to debunking myths and showcasing practical steps to help individuals nurture their gut microbiome,” said Leucine Rich Bio co-founder & director Dr Debojyoti Dhar.
“By addressing key factors like work-life balance, regular exercise, and cutting down on smoking and alcohol, individuals can significantly boost their gut’s overall well-being,” added Dr Dhar.
Commenting on the same Leucine Rich Bio CEO Kumar Sankaran stated “Driving innovation in gut health requires continuous investment in cutting-edge research. Through joint research initiatives and collaboration with experts, we are paving the way for advancements in personalized wellness solutions and planning to partner with the biggest diagnostic chains to enhance the awareness of gut health in the near future”
As the Happy Gut Mission campaign unfolds, Leucine Rich Bio encourages individuals to adopt a holistic approach to gut health, integrating scientifically backed practices with personal lifestyle preferences. With a focus on education, support, and sustainable habits, this campaign seeks to inspire lasting improvements in gut health and overall vitality.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
